Molecular basis of klotho: From gene to function in aging

Endocrine Reviews

Volumn 36, Issue 2, 2015, Pages 174-193

  Xu, Yuechi ^a   Sun, Zhongjie ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM10 ENDOPEPTIDASE; AMYLOID PRECURSOR PROTEIN; CALCIUM; CCAAT ENHANCER BINDING PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; EARLY GROWTH RESPONSE FACTOR 1; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GELATINASE B; GLYCOSIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERSTITIAL COLLAGENASE; JANUS KINASE 2; KLOTHO PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOMATOMEDIN C; STAT3 PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 5; VITAMIN D; BETA GLUCURONIDASE;

AGING; CALCIUM HOMEOSTASIS; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; ENZYME ACTIVITY; GENE; GENE FUNCTION; GENE LOCATION; GENE STRUCTURE; GENETIC TRANSCRIPTION; HOMOZYGOTE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; INDEL MUTATION; INSULIN SENSITIVITY; KIDNEY DISEASE; KLOTHO GENE; MINERAL METABOLISM; MUTATIONAL ANALYSIS; NONHUMAN; OXIDATIVE STRESS; PHOSPHATE METABOLISM; POINT MUTATION; PREMATURE AGING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; RICKETS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; VITAMIN D METABOLISM; VITAMIN D RESPONSIVE ELEMENT; WNT SIGNALING PATHWAY; GENETICS; METABOLISM; PHYSIOLOGY;

AGING; CALCIUM; GLUCURONIDASE; HUMANS; OXIDATIVE STRESS; PHOSPHATES; SIGNAL TRANSDUCTION; VITAMIN D; WNT SIGNALING PATHWAY;

EID: 84929391863     PISSN: 0163769X     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2013-1079     Document Type: Review

References (211)

1. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45-51.
2. Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science. 2005;309:1829-1833.
3. Masuda H, Chikuda H, Suga T, Kawaguchi H, Kuro-o M. Regulation of multiple ageing-like phenotypes by inducible klotho gene expression in klotho mutant mice. Mech Ageing Dev. 2005;126:1274-1283.
4. Wang Y, Sun Z. Current understanding of klotho. Ageing Res Rev. 2009;8:43-51.
5. Yamazaki Y, Imura A, Urakawa I, et al. Establishment of sandwich ELISA for soluble α-Klotho measurement: age- dependent change of solubleα-Klotho levels in healthy subjects. Biochem Biophys ResCommun. 2010;398:513-518.
6. Pedersen L, Pedersen SM, Brasen CL, Rasmussen LM. Soluble serum Klotho levels in healthy subjects. Comparison of two different immunoassays. Clin Biochem. 2013;46:1079-1083.
7. Siahanidou T, GaratziotiM,Lazaropoulou C, et al. Plasma soluble α-klotho protein levels in premature and term neonates:correlations with growth and metabolic parameters. Eur J Endocrinol. 2012;167:433-440.
8. Wang HL, Xu Q, Wang Z, et al. A potential regulatory single nucleotide polymorphism in the promoter of the Klotho gene may be associated with essential hypertension in the Chinese Han population. Clin Chim Acta. 2010;411:386-390.
9. Wang Y, Sun Z. Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension. 2009;54:810-817.
10. WangX, Sun Z.RNAisilencing of brain klotho potentiates cold-induced elevation of blood pressure via the endothelin pathway. Physiol Genomics. 2010;41:120-126.
11. Wang Y, Sun Z. Antiaging gene Klotho regulates endothelin-1 levels and endothelin receptor subtype B expression in kidneys of spontaneously hypertensive rats. J Hypertens. 2014;32:1629-1636; discussion 1636.
12. Zhou X, Chen K, Lei H, Sun Z. Klotho gene deficiency causes salt-sensitive hypertension via monocyte chemotactic protein-1/CC chemokine receptor 2-mediated inflammation. J Am Soc Nephrol. 2015;26:121-132.
13. Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun. 2001;280:1015-1020.
14. Lin Y, Kuro-o M, Sun Z. Genetic deficiency of anti-aging gene klotho exacerbates early nephropathy in STZ-induced diabetes in male mice. Endocrinology. 2013;154:3855-3863.
15. Lin Y, Sun Z. Antiaging gene Klotho enhances glucoseinduced insulin secretion by up-regulating plasma membrane levels of TRPV2 in MIN6 β-cells. Endocrinology. 2012;153:3029-3039.
16. Lin Y, Sun Z. In vivo pancreatic β cell-specific expression of anti-aging gene Klotho, a novel approach for preserving β cells in type II diabetes. Diabetes. 2014.
17. Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M, Nabeshima Y. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun. 1998;242:626-630.
18. Sugano Y, Lardelli M. Identification and expression analysis of the zebrafish orthologue of Klotho.Dev Genes Evol. 2011;221:179-186.
19. Château MT, Araiz C, Descamps S, Galas S. Klotho interferes with a novel FGF-signalling pathway and insulin/Igflike signalling to improve longevity and stress resistance in Caenorhabditis elegans. Aging (Albany NY). 2010;2:567-581.
20. Janson L, Pettersson U. Cooperative interactions between transcription factors Sp1 and OTF-1. Proc Natl Acad Sci USA. 1990;87:4732-4736.
21. Whyte DA, Li C, Thomson RB, et al. Ksp-cadherin gene promoter. I. Characterization and renal epithelial cell-specific activity. Am J Physiol. 1999;277:F587-F598.
22. Snape AM, Winning RS, Sargent TD. Transcription factor AP-2 is tissue-specific in Xenopus and is closely related or identical to keratin transcription factor 1 (KTF-1). Development. 1991;113:283-293.
23. Sosa-Pineda B, Chowdhury K, Torres M, Oliver G, Gruss P. The Pax4 gene is essential for differentiation of insulinproducing β cells in the mammalian pancreas. Nature. 1997;386:399-402.
24. Perrotti D, Melotti P, Skorski T, Casella I, Peschle C, Calabretta B. Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity. Mol Cell Biol. 1995;15:6075-6087.
25. Hromas R, Davis B, Rauscher FJ 3rd, et al. Hematopoietic transcriptional regulation by the myeloid zinc finger gene, MZF-1. Curr Top Microbiol Immunol. 1996;211:159-164.
26. Kastner P, Chan S. Role of Ikaros in T-cell acute lymphoblastic leukemia. World J Biol Chem. 2011;2:108-114.
27. Turan K, Ata P. Effects of intra- and extracellular factors on anti-aging klotho gene expression. Genet Mol Res. 2011;10:2009-2023.
28. Schüle R, Muller M, Kaltschmidt C, Renkawitz R. Many transcription factors interact synergistically with steroid receptors. Science. 1988;242:1418-1420.
29. Merika M, Orkin SH. Functional synergy and physical interactions of the erythroid transcription factor GATA-1 with the Krüppel family proteins Sp1 and EKLF. Mol Cell Biol. 1995;15:2437-2447.
30. Zhang W, Shields JM, Sogawa K, Fujii-Kuriyama Y, Yang VW. The gut-enriched Krüppel-like factor suppresses the activity of the CYP1A1 promoter in an Sp1-dependent fashion. J Biol Chem. 1998;273:17917-17925.
31. Thurston RD, Larmonier CB, Majewski PM, et al. Tumor necrosis factor and interferon-ϒ down-regulate Klotho in mice with colitis. Gastroenterology. 2010;138:1384-1394.
32. Zhou Q, Lin S, Tang R, Veeraragoo P, PengW,WuR. Role of fosinopril and valsartan on klotho gene expression induced by angiotensin II in rat renal tubular epithelial cells. Kidney Blood Press Res. 2010;33:186-192.
33. Moreno JA, Izquierdo MC, Sanchez-Niño MD, et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J Am Soc Nephrol. 2011;22:1315-1325.
34. Komaba H, Goto S, Fujii H, et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 2010;77:232-238.
35. King GD, Rosene DL, Abraham CR. Promoter methylation and age-related downregulation of Klotho in rhesus monkey. Age (Dordr). 2012;34:1405-1419.
36. Azuma M, Koyama D, Kikuchi J, et al. Promoter methylation confers kidney-specific expression of the Klotho gene. FASEB J. 2012;26:4264-4274.
37. Young GH, Wu VC. KLOTHO methylation is linked to uremic toxins and chronic kidney disease. Kidney Int. 2012;81:611-612.
38. Sun CY, Chang SC, Wu MS. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int. 2012;81:640-650.
39. Lee J, Jeong DJ, Kim J, et al. The anti-aging geneKLOTHO is a novel target for epigenetic silencing in human cervical carcinoma. Mol Cancer. 2010;9:109.
40. Gan LH, Pan J, Chen SJ, Zhong J, Wang LJ. DNA methylation of ZIC1 and KLOTHO gene promoters in colorectal carcinomas and its clinicopathological significance [in Chinese]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2011;40:309-314.
41. Pan J, Zhong J, Gan LH, et al. Klotho, an anti-senescence related gene, is frequently inactivated through promoter hypermethylation in colorectal cancer. Tumour Biol. 2011;32:729-735.
42. WangL,WangX,WangX, et al. Klotho is silenced through promoter hypermethylation in gastric cancer.AmJ Cancer Res. 2011;1:111-119.
43. Rubinek T, Shulman M, Israeli S, et al. Epigenetic silencing of the tumor suppressor klotho in human breast cancer. Breast Cancer Res Treat. 2012;133:649-657.
44. Yahata K, Mori K, Arai H, et al. Molecular cloning and expression of a novel klotho-related protein. J Mol Med (Berl). 2000;78:389-394.
45. Ito S, Fujimori T, Furuya A, Satoh J, Nabeshima Y, Nabeshima Y. Impaired negative feedback suppression of bile acid synthesis in mice lacking βKlotho. J Clin Invest. 2005;115:2202-2208.
46. Ito S, Fujimori T, Hayashizaki Y, Nabeshima Y. Identification of a novel mouse membrane-bound family 1 glycosidase- like protein, which carries an atypical active site structure. Biochim Biophys Acta. 2002;1576:341-345.
47. Yaylaoglu MB, Titmus A, Visel A, Alvarez-Bolado G, Thaller C, Eichele G. Comprehensive expression atlas of fibroblast growth factors and their receptors generated by a novel robotic in situ hybridization platform. Dev Dyn. 2005;234:371-386.
48. Ito S, Kinoshita S, Shiraishi N, et al. Molecular cloning and expression analyses of mouse βklotho, which encodes a novel Klotho family protein. Mech Dev. 2000;98:115-119.
49. Kharitonenkov A, Dunbar JD, Bina HA, et al. FGF-21/ FGF-21 receptor interaction and activation is determined by βKlotho. J Cell Physiol. 2008;215:1-7.
50. Ogawa Y, Kurosu H, Yamamoto M, et al. βKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA. 2007;104:7432-7437.
51. Suzuki M, Uehara Y, Motomura-Matsuzaka K, et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol. 2008;22:1006-1014.
52. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5:426-437.
53. Adams AC, Kharitonenkov A. FGF21: the center of a transcriptional nexus in metabolic regulation. Curr Diabetes Rev. 2012;8:285-293.
54. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5:415-425.
55. Lundåsen T, Hunt MC, Nilsson LM, et al. PPARα is a key regulator of hepatic FGF21. Biochem Biophys Res Commun. 2007;360:437-440.
56. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007;282:26687-26695.
57. Lin BC, Wang M, Blackmore C, Desnoyers LR. Liver-specific activities of FGF19 require Klotho β. J Biol Chem. 2007;282:27277-27284.
58. Wu X, Ge H, Gupte J, et al. Co-receptor requirements for fibroblast growth factor-19 signaling. J Biol Chem. 2007;282:29069-29072.
59. Hotta Y, Nakamura H, KonishiM,et al. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology. 2009;150:4625-4633.
60. Razzaque MS. The role of Klotho in energy metabolism. Nat Rev Endocrinol. 2012;8:579-587.
61. Tomiyama K, Maeda R, Urakawa I, et al. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci USA. 2010;107:1666-1671.
62. Ding X, Boney-Montoya J, Owen BM, et al. βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 2012;16:387-393.
63. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627-1635.
64. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008;149:6018-6027.
65. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2:217-225.
66. Yu C, Wang F, Kan M, et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem. 2000;275:15482-15489.
67. Aizawa H, Saito Y, Nakamura T, et al. Downregulation of the Klotho gene in the kidney under sustained circulatory stress in rats. Biochem Biophys Res Commun. 1998;249:865-871.
68. Ohyama Y, Kurabayashi M, Masuda H, et al. Molecular cloning of rat klotho cDNA: markedly decreased expression of klotho by acute inflammatory stress. Biochem Biophys Res Commun. 1998;251:920-925.
69. Nagai R, Saito Y,OhyamaY, et al. Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci. 2000;57:738-746.
70. Yu J, Deng M, Zhao J, Huang L. Decreased expression of klotho gene in uremic atherosclerosis in apolipoprotein Edeficient mice. Biochem Biophys Res Commun. 2010;391:261-266.
71. Sugiura H, Yoshida T, Shiohira S, et al. Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis. Am J Physiol Renal Physiol. 2012;302:F1252-F1264.
72. Saito K, Ishizaka N, Mitani H, Ohno M, Nagai R. Iron chelation and a free radical scavenger suppress angiotensin II-induced downregulation of klotho, an anti-aging gene, in rat. FEBS Lett. 2003;551:58-62.
73. Mitobe M, Yoshida T, Sugiura H, Shirota S, Tsuchiya K, Nihei H. Oxidative stress decreases klotho expression in a mouse kidney cell line. Nephron Exp Nephrol. 2005;101:e67-e74.
74. Han DH, Piao SG, Song JH, et al. Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene. Transplantation. 2010;90:135-141.
75. Zuo Z, Lei H,WangX,WangY, SonntagW,Sun Z. Agingrelated kidney damage is associated with a decrease in klotho expression and an increase in superoxide production. Age (Dordr). 2011;33:261-274.
76. Adijiang A, Shimizu H, Higuchi Y, Nishijima F, Niwa T. Indoxyl sulfate reduces klotho expression and promotes senescence in the kidneys of hypertensive rats. J Ren Nutr. 2011;21:105-109.
77. Shimizu H, Bolati D, Adijiang A, et al. Indoxyl sulfate downregulates renal expression of Klotho through production of ROS and activation of nuclear factor-κB. Am J Nephrol. 2011;33:319-324.
78. Cheng X, Zhou Q, Lin S, Wu R. Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010;35:1048-1056.
79. Asai O, Nakatani K, Tanaka T, et al. Decreased renal α-Klotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretion. Kidney Int. 2012;81:539-547.
80. Kawano K, Ogata N, Chiano M, et al. Klotho gene polymorphisms associated with bone density of aged postmenopausal women. J Bone Miner Res. 2002;17:1744-1751.
81. Rhee EJ,OhKW,Yun EJ, et al. Relationship between polymorphisms G395A in promoter and C1818T in exon 4 of the KLOTHO gene with glucose metabolism and cardiovascular risk factors in Korean women. J Endocrinol Invest. 2006;29:613-618.
82. Kim Y, Jeong SJ, Lee HS, et al. Polymorphism in the promoter region of the klotho gene (G-395A) is associated with early dysfunction in vascular access in hemodialysis patients. Korean J Intern Med. 2008;23:201-207.
83. Shimoyama Y, Taki K, Mitsuda Y, Tsuruta Y, Hamajima N, Niwa T. KLOTHO gene polymorphisms G-395A and C1818T are associated with low-density lipoprotein cholesterol and uric acid in Japanese hemodialysis patients. Am J Nephrol. 2009;30:383-388.
84. Choi BH, Kim CG, Lim Y, Lee YH, Shin SY. Transcriptional activation of the human Klotho gene by epidermal growth factor in HEK293 cells; role of Egr-1. Gene. 2010;450:121-127.
85. Forster RE, Jurutka PW, Hsieh JC, et al. Vitamin D receptor controls expression of the anti-aging klotho gene in mouse and human renal cells. Biochem Biophys Res Commun. 2011;414:557-562.
86. Zhang H, Li Y, Fan Y, et al. Klotho is a target gene of PPAR-ϒ. Kidney Int. 2008;74:732-739.
87. Zhang R, Zheng F. PPAR-ϒ and aging: one link through klotho? Kidney Int. 2008;74:702-704.
88. Narumiya H, Sasaki S, Kuwahara N, et al. HMG-CoA reductase inhibitors up-regulate anti-aging klotho mRNA via RhoA inactivation in IMCD3 cells. Cardiovasc Res. 2004;64:331-336.
89. Kuwahara N, Sasaki S, Kobara M, et al. HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis. Int J Cardiol. 2008;123:84-90.
90. Sugiura H, Yoshida T, Mitobe M, Shiohira S, Nitta K, Tsuchiya K. Recombinant human erythropoietin mitigates reductions in renal klotho expression. Am J Nephrol. 2010;32:137-144.
91. Tang R, Zhou QL, Ao X, Peng WS, Veeraragoo P, Tang TF. Fosinopril and losartan regulate klotho gene and nicotinamide adenine dinucleotide phosphate oxidase expression in kidneys of spontaneously hypertensive rats. Kidney Blood Press Res. 2011;34:350-357.
92. Tataranni T, Biondi G, Cariello M, et al. Rapamycin-induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and Klotho expression. Am J Transplant. 2011;11:1656-1664.
93. KingGD,ChenC,HuangMM,et al. Identification of novel small molecules that elevate Klotho expression. Biochem J. 2012;441:453-461.
94. Mizuno I, Takahashi Y, Okimura Y, Kaji H, Chihara K. Upregulation of the klotho gene expression by thyroid hormone and during adipose differentiation in 3T3-L1 adipocytes. Life Sci. 2001;68:2917-2923.
95. Yamagishi T, Saito Y, Nakamura T, et al. Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. Hypertens Res. 2001;24:705-709.
96. Bloch L, Sineshchekova O, Reichenbach D, et al. Klotho is a substrate for α-, β- and ϒ-secretase. FEBS Lett. 2009;583:3221-3224.
97. Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci USA. 2007;104:19796-19801.
98. Li H, Wang B, Wang Z, et al. Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Proc Natl Acad Sci USA. 2010;107:17362-17367.
99. Imura A, Iwano A, Tohyama O, et al. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett. 2004;565:143-147.
100. Rye CS, Withers SG. Glycosidase mechanisms. Curr Opin Chem Biol. 2000;4:573-580.
101. Hayashi Y, Okino N, Kakuta Y, et al. Klotho-related protein is a novel cytosolic neutral β-glycosylceramidase. J Biol Chem. 2007;282:30889-30900.
102. Noguchi J, Hayashi Y, Baba Y, et al. Crystal structure of the covalent intermediate of human cytosolic β-glucosidase. Biochem Biophys Res Commun. 2008;374:549-552.
103. Tohyama O, Imura A, Iwano A, et al. Klotho is a novel β-glucuronidase capable of hydrolyzing steroid β-glucuronides. J Biol Chem. 2004;279:9777-9784.
104. Chang Q, Hoefs S, van der KempAW, Topala CN, Bindels RJ, Hoenderop JG. The β-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science. 2005;310:490-493.
105. Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro-O M, Huang CL. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci USA. 2008;105:9805-9810.
106. ChaSK,HuMC,Kurosu H, Kuro-oM,MoeO,HuangCL. Regulation of renal outer medullary potassium channel and renal K(+) excretion by Klotho. Mol Pharmacol. 2009;76:38-46.
107. Ichikawa S, Imel EA, Kreiter ML, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest. 2007;117:2684-2691.
108. Arking DE, Krebsova A, MacekMSr, et al. Association of human aging with a functional variant of klotho. Proc Natl Acad Sci USA. 2002;99:856-861.
109. Arking DE, Atzmon G, Arking A, Barzilai N, Dietz HC. Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ Res. 2005;96:412-418.
110. Deary IJ, Harris SE, FoxHC,et al.KLOTHOgenotype and cognitive ability in childhood and old age in the same individuals. Neurosci Lett. 2005;378:22-27.
111. Zhou L, Li Y, Zhou D, Tan RJ, Liu Y. Loss of Klotho contributes to kidney injury by derepression of Wnt/β- catenin signaling. J Am Soc Nephrol. 2013;24:771-785.
112. Wolf I, Laitman Y, Rubinek T, et al. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin. Oncogene. 2010;29:26-33.
113. Nzietchueng R, El Shamieh S, Benachour H, et al. Klotho KL-VS genotype is involved in blood pressure regulation. Clin Chim Acta. 2011;412:1773-1777.
114. Utsugi T, Ohno T, Ohyama Y, et al. Decreased insulin production and increased insulin sensitivity in the klotho mutant mouse, a novel animal model for human aging. Metabolism. 2000;49:1118-1123.
115. Wolf I, Levanon-Cohen S, Bose S, et al. Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene. 2008;27:7094-7105.
116. Chen B, Wang X, Zhao W, Wu J. Klotho inhibits growth and promotes apoptosis in human lung cancer cell line A549. J Exp Clin Cancer Res. 2010;29:99.
117. Lorenzi O, Veyrat-Durebex C, Wollheim CB, et al. Evidence against a direct role of klotho in insulin resistance. Pflugers Arch. 2010;459:465-473.
118. Mori K, Yahata K, Mukoyama M, et al. Disruption of klotho gene causes an abnormal energy homeostasis in mice. Biochem Biophys Res Commun. 2000;278:665-670.
119. Yamamoto M, Clark JD, Pastor JV, et al. Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem. 2005;280:38029-38034.
120. Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest. 2001;108:1359-1367.
121. Armoni M, Harel C, Karni S, et al. FOXO1 represses peroxisome proliferator-activated receptor-ϒ1 and -ϒ2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. J Biol Chem. 2006;281:19881-19891.
122. Chihara Y, Rakugi H, Ishikawa K, et al. Klotho protein promotes adipocyte differentiation. Endocrinology. 2006;147:3835-3842.
123. Cristancho AG, Lazar MA. Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol. 2011;12:722-734.
124. Zhang JW, Klemm DJ, Vinson C, Lane MD. Role of CREB in transcriptional regulation of CCAAT/enhancer-binding protein β gene during adipogenesis. J Biol Chem. 2004;279:4471-4478.
125. ClarksonRW,ChenCM,Harrison S, Wells C, Muscat GE, Waters MJ. Early responses of trans-activating factors to growth hormone in preadipocytes: differential regulation of CCAAT enhancer-binding protein-beta (C/EBP beta) and C/EBP delta. Mol Endocrinol. 1995;9:108-120.
126. Chen J, Kunos G, Gao B. Ethanol rapidly inhibits IL-6- activated STAT3 and C/EBP mRNA expression in freshly isolated rat hepatocytes. FEBS Lett. 1999;457:162-168.
127. Zhu T, Lobie PE. Janus kinase 2-dependent activation of p38 mitogen-activated protein kinase by growth hormone. Resultant transcriptional activation of ATF-2 and CHOP, cytoskeletal re-organization and mitogenesis. J Biol Chem. 2000;275:2103-2114.
128. Birsoy K, Chen Z, Friedman J. Transcriptional regulation of adipogenesis by KLF4. Cell Metab. 2008;7:339-347.
129. Wang D, Zhou Y, Lei W, et al. Signal transducer and activator of transcription 3 (STAT3) regulates adipocyte differentiation via peroxisome-proliferator-activated receptor ϒ (PPARϒ). Biol Cell. 2010;102:1-12.
130. Zhang K, Guo W, Yang Y,WuJ. JAK2/STAT3 pathway is involved in the early stage of adipogenesis through regulating C/EBPβ transcription. J Cell Biochem. 2011;112:488-497.
131. Mikkelsen TS, Xu Z, Zhang X, et al. Comparative epigenomic analysis of murine and human adipogenesis. Cell. 2010;143:156-169.
132. Steger DJ, Grant GR, Schupp M, et al. Propagation of adipogenic signals through an epigenomic transition state. Genes Dev. 2010;24:1035-1044.
133. Siersbæk R, Nielsen R, John S, et al. Extensive chromatin remodelling and establishment of transcription factor 'hotspots' during early adipogenesis. EMBO J. 2011;30:1459-1472.
134. Liu H, Fergusson MM, Castilho RM, et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science. 2007;317:803-806.
135. Satoh M, Nagasu H, Morita Y, Yamaguchi TP, Kanwar YS, Kashihara N. Klotho protects against mouse renal fibrosis by inhibiting Wnt signaling. Am J Physiol Renal Physiol. 2012;303:F1641-F1651.
136. Camilli TC, Xu M, O'Connell MP, et al. Loss of Klotho during melanoma progression leads to increased filamin cleavage, increased Wnt5A expression, and enhanced mel- anoma cell motility. Pigment Cell Melanoma Res. 2011;24:175-186.
137. Hiyama A, Arai F, Sakai D, Yokoyama K, Mochida J. The effects of oxygen tension and antiaging factor Klotho on Wnt signaling in nucleus pulposus cells. Arthritis Res Ther. 2012;14:R105.
138. Uchihashi K, Nakatani T, Goetz R,MohammadiM,HeX, Razzaque MS. FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6. Contrib Nephrol. 2013;180:124-137.
139. Chen TH, Kuro-O M, Chen CH, et al. The secreted Klotho protein restores phosphate retention and suppresses accelerated aging in Klotho mutant mice. Eur J Pharmacol. 2013;698:67-73.
140. Leppänen A, Stowell S, Blixt O, Cummings RD. Dimeric galectin-1 binds with high affinity to α2,3-sialylated and non-sialylated terminal N-acetyllactosamine units on surface- bound extended glycans. J Biol Chem. 2005;280:5549-5562.
141. Olauson H, Lindberg K, Amin R, et al. Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J Am Soc Nephrol. 2012;23:1641-1651.
142. Kusaba T, Okigaki M, Matui A, et al. Klotho is associated with VEGF receptor-2 and the transient receptor potential canonical-1 Ca2+ channel to maintain endothelial integrity. Proc Natl Acad Sci USA. 2010;107:19308-19313.
143. Imura A, Tsuji Y, Murata M, et al. α-Klotho as a regulator of calcium homeostasis. Science. 2007;316:1615-1618.
144. Nabeshima Y. The discovery of α-Klotho and FGF23 unveiled new insight into calcium and phosphate homeostasis. Cell Mol Life Sci. 2008;65:3218-3230.
145. Drüeke TB. Klotho, FGF23, and FGF receptors in chronic kidney disease: a yin-yang situation? Kidney Int. 2010;78:1057-1060.
146. Tanaka Y, Deluca HF. Role of 1,25-dihydroxyvitamin D3 in maintaining serum phosphorus and curing rickets. Proc Natl Acad Sci USA. 1974;71:1040-1044.
147. Wilz DR, Gray RW, Dominguez JH, Lemann J Jr. Plasma 1,25-(OH)2-vitamin D concentrations and net intestinal calcium, phosphate, and magnesium absorption in humans. Am J Clin Nutr. 1979;32:2052-2060.
148. Moallem E, Kilav R, Silver J, Naveh-Many T. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem. 1998;273:5253-5259.
149. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26:345-348.
150. Kos CH, Tihy F, Murer H, Lemieux N, Tenenhouse HS. Comparative mapping of Na+-phosphate cotransporter genes, NPT1 and NPT2, in human and rabbit. Cytogenet Cell Genet. 1996;75:22-24.
151. Xu H, Bai L, Collins JF, Ghishan FK. Age-dependent regulation of rat intestinal type IIb sodium-phosphate cotransporter by 1,25-(OH)(2) vitamin D(3).AmJ Physiol Cell Physiol. 2002;282:C487-C493.
152. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001;98:6500-6505.
153. Farrow EG, Davis SI, Summers LJ, White KE. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol. 2009;20:955-960.
154. Farrow EG, Yu X, Summers LJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA. 2011;108:E1146-E1155.
155. Farrow EG, Imel EA, White KE. Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and βKlotho). Best Pract Res Clin Rheumatol. 2011;25:735-747.
156. Benet-Pagès A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM. FGF23 is processed by proprotein convertases but not by PHEX. Bone. 2004;35:455-462.
157. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281:6120-6123.
158. Li H, Martin A, David V, Quarles LD. Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. AmJ Physiol Endocrinol Metab. 2011;300:E508-E517.
159. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770-774.
160. Yamazaki Y, Tamada T, Kasai N, et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res. 2008;23:1509-1518.
161. Goetz R, Nakada Y, Hu MC, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci USA. 2010;107:407-412.
162. Liu S, Gupta A, Quarles LD. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens. 2007;16:329-335.
163. Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens. 2006;15:437-441.
164. Medici D, Razzaque MS, Deluca S, et al. FGF-23-Klotho signaling stimulates proliferation and prevents vitamin Dinduced apoptosis. J Cell Biol. 2008;182:459-465.
165. Beckman MJ, Tadikonda P, Werner E, Prahl J, Yamada S, DeLuca HF. Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry. 1996;35:8465-8472.
166. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001;60:2079-2086.
167. Hoenderop JG, Dardenne O, Van Abel M, et al. Modulation of renal Ca2+ transport protein genes by dietary Ca2+ and 1,25-dihydroxyvitamin D3 in 25-hydroxyvitamin D3-1α-hydroxylase knockout mice. FASEB J. 2002;16:1398-1406.
168. Astecker N, Bobrovnikova EA, Omdahl JL, et al. C-25 hydroxylation of1α,24(R)-dihydroxyvitaminD3is catalyzed by 25-hydroxyvitamin D3-24-hydroxylase (CYP24A1): me tabolism studies with human keratinocytes and rat recombinant CYP24A1. Arch Biochem Biophys. 2004;431:261-270.
169. Hoenderop JG, Chon H, Gkika D, et al. Regulation of gene expression by dietary Ca2+ in kidneys of 25-hydroxyvitamin D3-1 α-hydroxylase knockout mice. Kidney Int. 2004;65:531-539.
170. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561-568.
171. Shimada T, Yamazaki Y, Takahashi M, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005;289:F1088-F1095.
172. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003-4008.
173. Wetmore JB, Quarles LD. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clin Pract Nephrol. 2009;5:24-33.
174. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure:a bone parathyroid feedback loop.AmJ Physiol Renal Physiol. 2010;299:F882-F889.
175. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol. 2003;17:2393-2403.
176. Stubbs JR, Liu S, Tang W, et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007;18:2116-2124.
177. Liu S, Zhou J, Tang W, Menard R, Feng JQ, Quarles LD. Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab. 2008;295:E254-E261.
178. Sitara D, Razzaque MS, St-Arnaud R, et al. Genetic ablation of vitaminDactivation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol. 2006;169:2161-2170.
179. Morishita K, Shirai A, Kubota M, et al. The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr. 2001;131:3182-3188.
180. Razzaque MS, Sitara D, Taguchi T, St-Arnaud R, Lanske B. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J. 2006;20:720-722.
181. OhnishiM,Nakatani T, Lanske B, RazzaqueMS.Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitaminD1α-hydroxylase. Kidney Int. 2009;75:1166-1172.
182. Nakatani T, Sarraj B, Ohnishi M, et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J. 2009;23:433-441.
183. Nakatani T, Ohnishi M, Razzaque MS. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB J. 2009;23:3702-3711.
184. Brownstein CA, Zhang J, Stillman A, et al. Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse. Endocrinology. 2010;151:492-501.
185. OhnishiM,RazzaqueMS.Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J. 2010;24:3562-3571.
186. Beck L, Karaplis AC, Amizuka N, Hewson AS, Ozawa H, Tenenhouse HS. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci USA. 1998;95:5372-5377.
187. Kuro-o M. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol. 2013;9:650-660.
188. Ohnishi M, Nakatani T, Lanske B, Razzaque MS. In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25- dihydroxyvitamin D levels. Circ Cardiovasc Genet. 2009;2:583-590.
189. Dërmaku-Sopjani M, Kolgeci S, Abazi S, Sopjani M. Significance of the anti-aging protein Klotho. Mol Membr Biol. 2013;30:369-385.
190. Xie J, Cha SK, An SW, Kuro-O M, Birnbaumer L, Huang CL. Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun. 2012;3:1238.
191. Ganesh SK, StackAG,LevinNW,Hulbert-Shearon T, Port FK. Association of elevated serum PO(4),Cax PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J AmSoc Nephrol. 2001;12:2131-2138.
192. Stenvinkel P, Larsson TE. Chronic kidney disease: a clinical model of premature aging. Am J Kidney Dis. 2013;62:339-351.
193. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74:148-157.
194. Bergwitz C, Jüppner H. FGF23 and syndromes of abnormal renal phosphate handling. Adv Exp Med Biol. 2012;728:41-64.
195. Unger RH. Klotho-induced insulin resistance: a blessing in disguise? Nat Med. 2006;12:56-57.
196. Emerling BM, Weinberg F, Liu JL, Mak TW, Chandel NS. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci USA. 2008;105:2622-2627.
197. Haruna Y, Kashihara N, Satoh M, et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci USA. 2007;104:2331-2336.
198. Izbeki F, Asuzu DT, Lorincz A, et al. Loss of Kitlow progenitors, reduced stem cell factor and high oxidative stress underlie gastric dysfunction in progeric mice. J Physiol. 2010;588:3101-3117.
199. Wang Y, Kuro-o M, Sun Z. Klotho gene delivery suppresses Nox2 expression and attenuates oxidative stress in rat aortic smooth muscle cells via thecAMP-PKApathway. Aging Cell. 2012;11:410-417.
200. Hsieh CC, Kuro-o M, Rosenblatt KP, Brobey R, Papaconstantinou J. The ASK1-Signalosome regulates p38 MAPK activity in response to levels of endogenous oxidative stress in the Klotho mouse models of aging. Aging (Albany NY). 2010;2:597-611.
201. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2012;48:158-167.
202. de Oliveira RM. Klotho RNAi induces premature senescence of human cells via a p53/p21 dependent pathway. FEBS Lett. 2006;580:5753-5758.
203. Maekawa Y, Ohishi M, Ikushima M, et al. Klotho protein diminishes endothelial apoptosis and senescence via a mitogen- activated kinase pathway. Geriatr Gerontol Int. 2011;11:510-516.
204. Niwa T, Shimizu H. Indoxyl sulfate induces nephrovascular senescence. J Ren Nutr. 2012;22:102-106.
205. Doi S, Zou Y, Togao O, et al. Klotho inhibits transforming growth factor-β1 (TGF-β1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem. 2011;286:8655-8665.
206. Abramovitz L, Rubinek T, Ligumsky H, et al. KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer. Clin Cancer Res. 2011;17:4254-4266.
207. Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Yu H. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression. Cancer Invest. 2008;26:185-192.
208. Hu MC, Shi M, Zhang J, et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 2010;24:3438-3450.
209. Dërmaku-Sopjani M, Sopjani M, Saxena A, et al. Downregulation of NaPi-IIa and NaPi-IIb Na-coupled phosphate transporters by coexpression of Klotho. Cell Physiol Biochem. 2011;28:251-258.
210. Kawai M, Kinoshita S, Kimoto A, et al. FGF23 suppresses chondrocyte proliferation in the presence of soluble α-Klotho both in vitro and in vivo. J Biol Chem. 2013;288:2414-2427.
211. Smith RC, O'Bryan LM, Farrow EG, et al. Circulating βKlotho influences phosphate handling by controlling FGF23 production. J Clin Invest. 2012;122:4710-4715.